A new report suggests drug makers are profiting from the waste.
Its Caremark unit covers some 25 million U.S. customers
The industry worries it's a step toward price controls.
More generics are needed to create competition — but can the FDA approve them fast enough?
It's not just a few bad players, as Congressional hearing puts drug costs in focus.